NCT04928313View on ClinicalTrials.gov

Safety and Effectiveness of Cinnomer® (Glatiramer Acetate) in Multiple Sclerosis (MS) Treatment in Iran

CompletedOBSERVATIONAL
Enrollment

368

Participants

Timeline

Start Date

April 12, 2015

Primary Completion Date

February 17, 2020

Study Completion Date

February 17, 2020

Conditions
Relapsing Multiple Sclerosis
Interventions
DRUG

Glatiramer Acetate

Cinnomer® was injected subcutaneously 3 times per week at least 48 hours apart.

Sponsors

Lead Sponsor

Cinnagen
All Listed Sponsors
lead

Cinnagen

INDUSTRY